First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
Thesis: Anika Therapeutics: the story is balanced — MONOVISC and ORTHOVISC sales volumes and market share in US viscosupplementation market (estimated $500-600M annually)
value/turnaround - The stock trades at 1.0x book value and 1.9x sales with negative profitability…
Rising interest rates create modest headwinds through two channels: (1) higher discount rates compress valuation multiples for unprofitable…
Watch on earnings: US viscosupplementation market size and ANIK's unit volume share (MONOVISC/ORTHOVISC injection volumes), Medicare reimbursement rates for CPT codes 20610/20611 (joint injection procedures), Quarterly operating cash flow and cash balance relative to quarterly burn rate.
One Sentence Summary:
Anika Therapeutics: the story is balanced — monovisc and orthovisc sales volumes and market share in us viscosupplementation market (estimated $500-600m annually).
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.